2014 Annual Meeting | 1HC.001 - Clinical Approach to Muscle Disease

Date Saturday 04/26/14

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Andrew Mammen, MD, PhD

Topic(s)

Learning Objectives Participants should be familiar with the differential diagnoses and how to evaluate and treat patients with different myopathies.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
08:00 AM - 08:50 AM		Clinical Approach to the Patient with Muscle Disease Carlayne E. Jackson, MD, FAAN
08:50 AM - 09:40 AM		Muscular Dystrophy: Diagnosis, Management, and Future Directions Kathryn R. Wagner, MD, PhD
09:40 AM - 09:50 AM		Questions and Answers
09:50 AM - 10:05 AM		Break
10:05 AM - 10:55 AM		Channelopathies Richard J. Barohn, MD, FAAN
10:55 AM - 11:45 AM		Acquired Myopathies Andrew Mammen, MD, PhD
11:45 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Andrew Mammen, MD, PhD	Dr. Mammen has received research support from National Institutes of Health. The institution of an immediate family member of Dr. Mammen has received research support from National Institutes of Health. Dr. Mammen has received intellectual property interests from a discovery or technology relating to health care.
Richard J. Barohn, MD, FAAN	Dr. Barohn has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for NuFactor. The institution of Dr. Barohn has received research support from FDA OPD R01. Dr. Barohn has received intellectual property interests from a discovery or technology relating to health care.
Carlayne E. Jackson, MD, FAAN	Dr. Jackson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe Pharma America. Dr. Jackson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for AAN.
Kathryn R. Wagner, MD, PhD	Dr. Wagner has received personal compensation for serving as an employee of F. Hoffmann-La Roche Ltd. Dr. Wagner has stock in F. Hoffmann-La Roche.